The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
via Google News
The Latest on: RNA editing
- In Editing RNA, Researchers See Endless Possibilitieson December 1, 2021 at 10:27 am
RNA editing has been in DNA editing's shadow for nearly a decade, but recent investments in the technology could bring it into the limelight.
- Top 10 RNA-Based Biopharmason November 24, 2021 at 9:37 am
GEN’s new updated A-List of top companies in RNA-based biotech encompassing not only developers of vaccines and drugs based on various forms of RNA, but developers of RNA-based platform technologies.
- ProQR to Webcast Virtual Analyst Event on November 18on November 11, 2021 at 4:00 am
The QR-421a, QR-1123, QR-504a, and RNA editing platform technologies will also be featured. ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for ...
- Wave Life Sciences Ltd. (WVE) CEO Paul Bolno on Q3 2021 Results - Earnings Call Transcripton November 10, 2021 at 12:05 pm
Today, I will start with opening remarks after which Chandra will walk through how we are building a pipeline of RNA editing therapeutics with AIMers. Mike will then provide an update on our ...
- Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Updateon November 10, 2021 at 5:19 am
“RNA editing is a novel therapeutic modality that greatly expands our landscape of addressable genetically defined diseases. We are leading the way in this new field and quickly working toward ...
- EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapieson November 9, 2021 at 5:45 am
BEIJING & CAMBRIDGE, Mass., November 09, 2021--(BUSINESS WIRE)--EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for ...
- EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapieson November 9, 2021 at 5:27 am
“This collaboration allows us to leverage our expertise and experience to help translate EdiGene’s RNA base editing technology into transformative medicines that can benefit patients with ...
- EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on in Vivo RNA Editing Therapieson November 9, 2021 at 5:05 am
Under the partnership, EdiGene’s U.S.-based R&D Center will work with the David Gamm Laboratory at the University of Wisconsin-Madison to evaluate the pharmacological property of LEAPER™ RNA base ...
- Origin of Hepatitis δ Viruson November 5, 2021 at 5:00 pm
RNA editing by an adenosine deaminase that acts on dsRNA during replication leads to translation of a longer protein, large δ antigen, which together with HBV envelope proteins is essential for ...
- Cephalopods RNA Editing (IMAGE)on August 6, 2021 at 6:26 pm
who show behaviorally complex cephalopods use extensive RNA editing to diversify their neural proteome at the cost of limiting genomic sequence flexibility and evolution. Disclaimer: AAAS and ...
via Bing News